The APOLLO study is being conducted to help improve kidney transplant results and ensure the safety of living kidney donors. This is done through examining a gene called apolipoprotein L1 (APOL1). Genes are part of our DNA that decide things like our eye color. Some changes in the APOL1 gene can lead to kidney disease. People from African, Afro-Caribbean, Hispanic Black, or African American backgrounds are more likely to have these APOL1 changes. The study will look at DNA from kidney donors and recipients to see how these gene changes affect kidney transplants. The research is supported by the National Institutes of Health (NIH) and focuses on donors with recent African ancestry. This means their genetic makeup is similar to people living in Africa today. The study is in its second phase, starting in September 2023, and will last for two more years. Only living donors with recent African ancestry will be recruited during this phase.

• Participation is only for living donors with recent African ancestry.
• Study will continue for two years with no new transplant recipients being recruited.
• Consent is necessary for participation in this study.